Please join PPMD and Wave Life Sciences for a community webinar on Tuesday, April 1, 2025 at 1:00PM ET. The Wave team will provide an update on the company’s Phase 2 FORWARD-53 trial of WVE-N531, Wave’s exon skipping oligonucleotide being investigated for the treatment of individuals with Duchenne who are amenable to exon 53 skipping. Wave will discuss the recently released FORWARD-53 data and answer questions from the community.

Please submit questions in advance here.

Please register here.